同时，佛山持续以招大引强开拓增量，设立200亿元新动能产业基金，工业用地供应量全省第一，吸引 超3000个亿元以上项目落地，签约投资总额达1.8万亿元，带动工业投资近7000亿元、年均增长13%。 创新是引领发展的第一动力。佛山还积极以创新裂变激活动能，获批建设国家创新型城市，获省级科学 技术奖数量连续6年居全省地级市首位。季华实验室牵头实施先进制造装备重大科技工程，仙湖实验室 获批建设国家能源重点实验室，蓝橙实验室加快建设重载机器人全国重点实验室，在新型显示、新能 源、机器人等领域关键核心技术实现多点突破。 改革是激发活力的关键一招。五年来，佛山勇闯改革"深水区"，摸索出全域土地综合整治、老旧工业园 改造、商事制度改革等一批在全省乃至全国叫得响的"佛山经验"。作为民营经济大市，佛山在全国率先 出台服务市场主体的地方性法规——《佛山市市场主体服务条例》，营商环境评价连续三年居全省地级 市首位。目前，全市经营主体突破172万户，比五年前增长83.1%。 在推进城乡区域协调发展方面，佛山以头号力度推进"百县千镇万村高质量发展工程"，连续两年获全省 考核"优秀"。其中，佛山以建设全省首个城乡区域协调发展改革创新实验 ...

文｜董柳 2025年末，这一时间节点的重要性对菏泽来说不言而喻。 这是"十四五"与"十五五"接力的风口，亦是突破菏泽鲁西崛起三年行动计划（2023-2025年）的最后一年。 "十四五"的成绩单，势必成为丈量"突破菏泽，鲁西崛起"成效的标尺。 2025 年末，菏泽市接连召开"决胜'十四五'续写新篇章" 系列主题新闻发布会，为这座鲁西南城市五年来的发展写 下生动注脚。从科技创新专场披露的"连续两年全社会研发经费投入增速全省第一"，到自然资源和规划专场展示 的"100% 采煤塌陷地治理率"，一组组硬核数据、一个个突破性成果，勾勒出菏泽以创新破局、以产业筑基、以绿 色赋能的高质量发展轨迹，更兑现着"后来居上"的时代嘱托。 五年来，这座城市深入贯彻新发展理念，以创新驱动为引擎，以产业升级为抓手，在科技创新、医药产业建设等 领域实现突破性进展，为经济社会发展注入强劲动能，也为未来发展擘画了清晰蓝图。 医药崛起，全产业链打造鲁西南健康产业集群 在菏泽的产业版图中，生物医药产业始终是 "重头戏"。 创新驱动，锻造高质量发展引擎 "十四五"期间，菏泽市以"国际知名、国内一流、全省最优"为目标，构建起覆盖"种植—研发—制造—流通 ...

证券日报网讯12月17日，航宇微（300053）在互动平台回答投资者提问时表示，面对商业航天蓬勃发展 的契机，公司将坚持创新驱动，持续深化产品研发与性能优化，不断巩固竞争优势，并全力加大市场拓 展力度；同时，公司将密切关注行业前沿动态及技术发展趋势，积极挖掘新的业务增长点，推动业务规 模稳步发展，以提升公司核心竞争力。关于机构调研等投资者关系活动，公司如有相关安排，将严格按 照法律法规及时履行信息披露义务。 ...

记者丨 冉黎黎 刘世锦。资料图 金融怎么为现阶段的高质量发展服务？刘世锦表示，很重要的一点，是需要有强大的资本市场 和强大的货币。 编辑丨 张伟贤 从资本市场来看，刘世锦指出，金融为实体经济服务，简单地说就是选项目，选出有市场、有 效益、有前景、风险可控的好项目，提升资源配置效率。随着我国经济进入高质量发展阶段， 经济增长复杂度是在增加的，金融体系选项目的能力也要相应提升，这就是由传统银行体系到 现代资本市场体系演进的底层逻辑。 由南方财经全媒体集团主办，21世纪经济报道承办，渣打银行战略支持，东方证券等支持 的"南方财经论坛2025年会"12月5日—6日在广州南方财经大厦举办。 在刘世锦看来，中国经济进入创新驱动阶段后，选项目的职能更多地由资本市场来承担。 与 此同时，也会看到全社会的资金更多地流向资本市场。按照法国经济学家皮凯蒂的研究，GDP 《中共中央关于制定国民经济和社会发展第十五个五年规划的建议》提出，加快建设金融强 国。这是"金融强国"首次写入五年规划建议。 与社会净资产的比例为1∶5—1∶6。"十五五"和以后更长一个时期，如果GDP能够保持4%—5% 的增长速度，每年将会形成不低于30万亿元的社 ...

新华社北京12月16日电 题：必须坚持政策支持和改革创新并举——学习领会"五个必须"做好明年经济 工作 新华社记者于佳欣、刘开雄、任军 日前召开的中央经济工作会议上，习近平总书记以"五个必须"概括做好新形势下经济工作新的认识 和体会。"必须坚持政策支持和改革创新并举"，是其中的重要内容。 既要政策给力，也要改革发力，深刻体现了习近平经济思想蕴含的治理智慧。越是面临复杂形势和 不确定因素，越要坚持政策支持和改革创新并举，增强其协同效应，如此才能夯实经济发展根基，不断 激发高质量发展的内生动力。 既要政策给力也要改革发力 "尽管面临着巨大冲击，中国经济依然表现出强劲韧性。"日前，国际货币基金组织（IMF）总裁格 奥尔基耶娃作出如是评价。 格奥尔基耶娃的话，道出近期多个国际组织上调中国经济增速预期背后的考量：中国政府推出更加 积极有为的宏观政策支撑了消费和投资，而持续深化的结构性改革则进一步释放了经济活力与潜力。 坚持政策支持和改革创新并举，是我国经济面对外部逆风承压前行，却依然保持向新向优的重要密 码。 "必须综合施策，既要加强宏观调控，减轻短期经济波动，又要不失时机地全面深化改革，向改革 要动力、要活力，推动经 ...

12月10日至11日，中央经济工作会议在北京举行，向期待已久的社会各方明确了2026年中国经济工作的重点方向和 任务。 多家券商及研究机构专业人士从核心方向、宏观政策和投资机会等多个维度进行了解读。 "会议部署的八大重点任务构成了2026年经济工作的施工图。其中，'内需主导'与'创新驱动'位居前两位，清晰地指 明了短期稳增长与中长期动能转换的路径。这些任务并非孤立，而是相互关联、协同推进的系统工程。"华福证券总裁助 理兼研究所所长任志强向《金融时报》记者讲述了他的学习体会。 中金公司首席宏观经济分析师张文朗认为，本次会议客观分析了中国经济面临的发展形势，不回避困难挑战，突出 问题导向，目标非常清晰，直接回应了市场和社会对消费、投资、房地产、企业账款、市场竞争秩序等一系列热点问题 的广泛关切。 总基调：稳中求进 会议明确了明年的经济工作政策取向为"稳中求进、提质增效"，其中"提质增效"是今年的新要求。 "政策总基调在'稳中求进'的基础上，增加了'提质增效'的政策取向。"在长城证券首席经济学家汪毅看来，对于明年 的经济工作，本次中央经济工作会议仍然以"稳"字当头，但是更加强调"增强政策前瞻性针对性协同性，持续扩大 ...

Core Viewpoint - The company Xin Feng Ming (603225.SH) is expanding its global presence by investing approximately $280 million in a 360,000 tons/year functional fiber project in Egypt, aiming to enhance its international market positioning and respond to global trade challenges [1][3]. Group 1: Investment and Expansion - The investment in Egypt will be executed through a wholly-owned subsidiary and aims to produce mainly coarse denier yarn, addressing the local market's polyester fiber shortage [3]. - The project is strategically positioned to mitigate trade barriers in the EU and Middle East, leveraging Egypt's geographical advantages to access African and Mediterranean markets [3]. - The funding for the project will come from the company's own resources and bank financing, ensuring that domestic operations remain unaffected [3]. Group 2: Industry Position and Capacity - Xin Feng Ming has established a comprehensive integrated layout in the polyester industry, with PTA production capacity reaching 7.7 million tons and expected to exceed 10 million tons by the end of 2025 [1][4]. - The company holds a 15% market share in the polyester filament market in China, ranking second in the industry, and leads in short fiber production with a capacity of 1.2 million tons [4]. Group 3: Financial Performance - For the first three quarters of 2025, the company reported revenues of 51.542 billion yuan, a year-on-year increase of 4.77%, and a net profit attributable to shareholders of 869 million yuan, up 16.56% [5]. - The company's total assets reached 59.985 billion yuan by the end of Q3 2025, providing substantial financial support for research and development as well as capacity expansion [2][5].

深耕疫苗领域十五载，中慧生物在差异化创新赛道上跑出了加速度。8月登陆港交所的中慧生物，凭借 首款覆盖6月龄及以上全人群的四价亚单位流感疫苗等核心产品筑牢竞争壁垒，其港股上市认购倍数超 4000倍。中慧生物董事长、总经理安有才日前在接受中国证券报记者专访时，全面拆解了公司的产品布 局、业绩兑现逻辑、募资投向及未来发展蓝图，明确以"创新驱动"为核心，通过产能扩张与国际化布 局，剑指2030年20亿元营收目标，力争跻身国内疫苗企业第一梯队。 差异化布局提升产品竞争力 中慧生物于今年8月11日登陆港交所，公司专注于创新疫苗及采用新技术的传统疫苗的研发、制造与商 业化。核心产品四价流感病毒亚单位疫苗（慧尔康欣）于2023年9月获批上市，今年9月获国家药监局扩 龄批准，适用人群从3岁及以上扩展至6月龄及以上，成为我国首款覆盖6月龄及以上全人群的亚单位流 感疫苗。目前，公司上海及泰州两大研发中心与中试平台正同步推进病毒性疫苗、细菌性疫苗、结合疫 苗、亚单位疫苗及mRNA疫苗等多条管线布局。 差异化定位是中慧生物的核心竞争力。安有才表示，公司自成立之初便确立了创新驱动的发展理念，拒 绝简单复制，聚焦国外四大巨头的创新品种进行 ...

Core Insights - Zhonghui Biotech has accelerated its differentiated innovation in the vaccine sector, successfully listing on the Hong Kong Stock Exchange in August with a subscription multiple exceeding 4000 times, driven by its core product, a quadrivalent subunit influenza vaccine [1][2] Group 1: Product Development and Market Position - The company focuses on innovative vaccines and traditional vaccines using new technologies, with its core product, the quadrivalent influenza vaccine (Hui Er Kang Xin), approved for all individuals aged 6 months and older, making it the first of its kind in China [1][2] - The quadrivalent influenza vaccine is priced at 319 yuan per dose, significantly higher than many competing products, supported by a complex purification process that requires five traditional vaccines to produce one subunit vaccine [2] - Since its market launch in September 2023, the quadrivalent vaccine has generated over 50 million yuan in revenue within three months, with projected revenues of 260 million yuan in 2024 and over 500 million yuan in 2025, demonstrating strong commercial viability [2] Group 2: Strategic Goals and Future Plans - The company aims to become a leading player in the domestic vaccine industry by 2030, targeting revenue of 2 billion yuan, with a strategic focus on "innovation-driven" development, quality leadership, management efficiency, and international expansion [3][5] - Zhonghui Biotech is exploring the development of a universal influenza vaccine and is advancing research in rabies vaccines using human embryonic cells, which offer advantages over traditional animal-derived cells [3][4] - Approximately 30% of the funds raised from the IPO will be allocated to existing products and the development of a diploid rabies vaccine, with plans for commercialization by 2027 [4] Group 3: International Expansion - The company has identified Southeast Asia, the Middle East, and parts of Latin America as key regions for international expansion, focusing on product registration in countries like the Philippines, Malaysia, Thailand, and Indonesia [5] - The international strategy includes leveraging existing production capabilities to efficiently produce vaccines for both hemispheres, with plans for business development projects related to the monkeypox vaccine in Africa, expected to materialize by 2026 [5]

Core Viewpoint - Zhonghui Biotech has accelerated its differentiated innovation in the vaccine sector, aiming for a revenue target of 2 billion yuan by 2030, positioning itself among the top domestic vaccine companies [1][3]. Product Differentiation and Competitive Edge - Zhonghui Biotech focuses on innovative vaccines and traditional vaccines using new technologies, with its core product being the quadrivalent subunit influenza vaccine, which received approval for a broader age range [2][3]. - The company has established a strong competitive edge through a differentiated product strategy, with 9 out of 13 vaccine candidates already receiving clinical approval [2][3]. - The quadrivalent influenza vaccine, Huierkangxin, is priced at 319 yuan per dose, significantly higher than many competitors, reflecting its complex production process [2][3]. Financial Performance and Projections - Since its market launch in September 2023, Huierkangxin has generated over 50 million yuan in revenue within three months, with projected revenues of 260 million yuan in 2024 and over 500 million yuan in 2025 [2][3]. Future Development Strategy - The company aims to achieve dual breakthroughs in performance and industry status through innovation, quality leadership, management efficiency, and international expansion [3][4]. - Zhonghui Biotech is developing a universal influenza vaccine and other innovative products, including rabies vaccines using human embryonic cells, which enhance adaptability in humans [3][4]. Fundraising and Investment Plans - The funds raised from the Hong Kong IPO will be allocated primarily to the industrialization of existing products and innovative vaccines, with 30% dedicated to expanding production capacity and advancing the rabies vaccine project [4][5]. - Another 30% of the funds will support the clinical development and industrialization of the shingles vaccine, with plans for it to enter phase III clinical trials by 2026 [5]. International Expansion - The company has identified Southeast Asia, the Middle East, and parts of Latin America as key markets for international expansion, focusing on regions where products can be registered for direct sales [5]. - Zhonghui Biotech is also pursuing business development projects for its monkeypox vaccine in Africa, with expectations for implementation by 2026 [5].